Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-09-22 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva publie ses résultats financiers du 1er semestre 2022 et fait un point sur ses activités
Earnings Release Classification · 99% confidence The document is titled "Inventiva publie ses résultats financiers du 1er semestre 2022 et fait un point sur ses activités" (Inventiva publishes its financial results for the first half of 2022 and provides an update on its activities). It contains detailed financial tables comparing H1 2022 results to H1 2021, discusses key financial metrics (revenue, R&D expenses, net loss), cash position, and cash flow statements for the six-month period ending June 30, 2022. The text explicitly states that the financial statements for the first half of 2022 were approved on September 20, 2022, and mentions that the limited review report from the statutory auditors is available. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year. Therefore, it aligns best with the Interim / Quarterly Report category (IR). It is not an Earnings Release (ER) because it contains detailed financial statements and extensive management discussion, not just highlights. H1 2022
2022-09-22 French
Inventiva reports its 2022 first-half financial results and provides a corporate update
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive report detailing Inventiva's financial results for the six months ended June 30, 2022. It includes a detailed income statement, balance sheet analysis, cash flow discussion, and management commentary on R&D progress. Although it mentions that the full Half-Year Financial Report is available on their website, the document itself contains the substantive financial data, tables, and analysis required to be classified as an Interim/Quarterly Report rather than just an announcement. H1 2022
2022-09-22 English
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
Capital/Financing Update Classification · 95% confidence The document is a formal announcement dated September 21, 2022, detailing a licensing and collaboration agreement between Inventiva and Sino Biopharm regarding the drug lanifibranor. It outlines financial terms (upfront payment, milestones, royalties) and strategic development plans. This type of announcement, which details a significant business transaction involving licensing, financing terms, and future development rights, fits best under the 'Capital/Financing Update' category, as it involves substantial financial considerations and restructuring of commercial rights, even though it is not a traditional debt/equity financing. However, given the specific definitions, the core event is a major business deal involving financial compensation and collaboration. Since there isn't a specific 'Licensing Agreement' code, I must choose the closest fit. 'CAP' (Capital/Financing Update) covers fundraising and capital structure changes, which this deal significantly impacts via upfront payments and future revenue streams. Alternatively, 'RNS' (Regulatory Filings/General Announcement) is a fallback. Given the focus on the \$12M upfront payment and up to \$290M in milestones, 'CAP' is a strong candidate representing a major financial transaction impacting the company's capital position. If the focus were purely on the drug development, 'IP' might apply, but the financial structure is central. I will classify it as 'CAP' due to the explicit financial terms of the deal, which is a form of capital/revenue structuring, and assign a high confidence score as it is a clear corporate action announcement.
2022-09-21 English
Inventiva et Sino Biopharm signent un accord de licence et de collaboration pour développer et commercialiser lanifibranor en Chine
Capital/Financing Update Classification · 95% confidence The document is a press release dated September 21, 2022, announcing a major licensing and collaboration agreement between Inventiva and Sino Biopharm regarding the drug lanifibranor for the Chinese market. It details financial terms (upfront payment, milestones, royalties) and strategic implications. This type of announcement, detailing a significant corporate transaction (licensing/partnership) and financial structure changes related to drug development, fits best under the 'Capital/Financing Update' category, as it involves substantial financial considerations and future revenue streams contingent on development milestones. While it relates to drug development, it is primarily a corporate/financial transaction announcement, not a standard financial report (10-K, IR, ER) or a presentation (IP). It is not a proxy statement (DEF 14A) or a general regulatory filing (RNS) given its specific nature. Therefore, CAP (Capital/Financing Update) is the most appropriate classification.
2022-09-21 French
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
Report Publication Announcement Classification · 98% confidence The document is an announcement titled "Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results." It explicitly states when the financial results will be published (September 21, 2022) and when a conference call will be held to discuss them (September 22, 2022). This document is not the actual financial report (which would be an IR or ER), nor is it the transcript of the call (CT). Instead, it is an announcement about the upcoming publication of reports and the associated conference call. According to Rule 2, if a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). The document length (4932 chars) is relatively short for a full financial report, and its primary function is to announce the schedule for the release of the '2022 half-year financial results' and the subsequent conference call.
2022-09-07 English
Inventiva annonce la date de publication et de présentation de ses résultats du 1 ? ? semestre 2022
Earnings Release Classification · 95% confidence The document is a press release from Inventiva announcing the date for the publication and presentation of its 'résultats du 1er semestre 2022' (first half 2022 financial results). It specifies when the results will be published (September 21st) and when a conference call/webcast will be held to discuss them (September 22nd). This structure—announcing the timing of financial results and the associated call—is characteristic of an Earnings Release (ER) or, if it were the actual detailed report, an Interim Report (IR). However, since this document is purely an announcement about *when* the results will be released and discussed, and not the results themselves, it fits best under the category of an Earnings Release (ER) which covers the initial announcement of periodical financial results (key highlights or the announcement thereof). Given the context of financial reporting announcements, ER is the most appropriate fit, as it precedes the full Interim Report (IR) or Earnings Call Transcript (CT). H1 2022
2022-09-07 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.